|
Jun 28
|
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
|
|
Jun 28
|
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
|
|
Jun 24
|
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
|
|
Jun 20
|
FDA lifts hold on PTC Huntington’s disease trial
|
|
Jun 20
|
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
|
|
May 20
|
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
|
|
May 20
|
PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna
|
|
May 20
|
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
|
|
May 20
|
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
|
|
May 14
|
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
|
|
May 2
|
PTC Therapeutics to Participate at Upcoming Investor Conferences
|
|
May 1
|
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
|
|
Apr 30
|
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
|
|
Apr 28
|
Industry Analysts Just Made A Captivating Upgrade To Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts
|
|
Apr 27
|
PTC Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
Apr 26
|
Sector Update: Health Care Stocks Edge Higher Late Afternoon
|
|
Apr 26
|
Q1 2024 PTC Therapeutics Inc Earnings Call
|
|
Apr 26
|
PTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...
|
|
Apr 26
|
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
|
|
Apr 25
|
PTC Therapeutics Q1 2024 Earnings: A Detailed Financial Review
|